QCM
NRIX icon

Quantinno Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Quantinno Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$343K Buy
22,133
+5,366
+32% +$89K ﹤0.01% 2959
2025
Q4 		$318K Buy
16,767
+163
+1% +$2.34K ﹤0.01% 2796
2025
Q3 		$153K Buy
+16,604
New +$172K ﹤0.01% 2828

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Quantinno Capital Management's NRIX Position: Q1 2026 in Review

Quantinno Capital Management increased its Nurix Therapeutics (NRIX) stake by 32% in Q1 2026, buying an estimated $89K and bringing the position to 22,133 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Quantinno Capital Management first reported a position in NRIX in Q3 2025 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Quantinno Capital Management held 22,133 shares of Nurix Therapeutics worth $343K as of Q1 2026.
  • Quantinno Capital Management bought 5,366 Nurix Therapeutics shares in Q1 2026, an estimated $89K.
  • Nurix Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #2959 holding.
  • Quantinno Capital Management first reported a position in Nurix Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.